What's in GNT Pharma's pipeline?

GNT Pharma has 5 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 4 in Phase 2, 0 in Phase 1.

Which companies overlap with GNT Pharma's portfolio?

No competitive overlap detected.

Subscribe to /feed/company/gnt-pharma.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

GNT Pharma pipeline: 0 marketed, 0 filed, 1 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 4 Phase 2 0 Phase 1 Live · 30-min refresh

Drug	Generic	Phase	Class	Target	Area	First approval
Neu2000KWL group	Neu2000KWL group	phase 3	NMDA receptor antagonist with antioxidant properties	NMDA receptor; free radical scavenger	Neurology

No regulatory actions in the last 90 days for this portfolio.

No PDUFA dates in the next 180 days for this portfolio.

No upcoming patent expiries for this portfolio.

No competitive overlap data.

Every new pipeline event for GNT Pharma:

Drug Landscape (2026). GNT Pharma — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/gnt-pharma. Accessed 2026-05-14.